Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 E573del |
| Therapy | Quizartinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 E573del | hematologic cancer | sensitive | Quizartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) decreased proliferation in transformed cells expressing FLT3 E573del in culture (PMID: 33914060). | 33914060 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (33914060) | Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis. | Full reference... |